Business Wire

BEARINGPOINT

6.2.2024 08:01:31 CET | Business Wire | Press release

Share
BearingPoint surpasses €1 billion full-year revenue target

Management and technology consultancy BearingPoint reports full-year revenues of €1.017 billion for 2023, a jump in year-on-year growth of 18%. The firm saw its bookings grow by 21% and delivered more than 1,800 projects in 32 countries. To support its growth, BearingPoint increased its workforce by 15% to more than 6,000 employees at the end of the year. For 2024, BearingPoint plans to hire more than 1,600 people as it accelerates its strategy and continues to expand globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240205345183/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Kiumars Hamidian, Managing Partner of BearingPoint. (Photo: Business Wire)

“2023 was a breakout year for BearingPoint,” said Kiumars Hamidian, Managing Partner of BearingPoint. “We reached our €1 billion in revenue target, and we did it sustainably, with a healthy growth position. We continue to see increasing demand for our services, especially our transformation programs and IP-driven digital assets. Growing demand is behind our expanding workforce, and we will continue strategic acquisitions in 2024 as we expand globally. I would like to thank all our amazing people and clients who made this success possible.”

Strategic acquisitions and global expansion

In 2023, BearingPoint completed five strategic acquisitions to enhance and strengthen its portfolio, particularly in the areas of sustainability (Korkia), Salesforce expertise (Smplicity), asset-backed securities (ABS) (TXS Securitization), and end-to-end services for IFS software and solutions through Arcwide, the joint venture of BearingPoint and IFS (bytics Group and Cedar Bay).

BearingPoint’s record hiring in 2023 was also due to expanding its expertise and services globally, especially in the US and China. In the US alone, BearingPoint achieved a revenue growth of 34%.

With more than 440 people and a strong revenue growth of 28%, the development of the Products business unit was another highlight for BearingPoint.

Continued investment in innovation, artificial intelligence and sustainability

BearingPoint continued to invest heavily in its innovative products and services and launched a generative AI hub, paving the way for businesses to unlock the transformative power of artificial intelligence. As one of the first consultancies BearingPoint published an ethical statement on the sustainable and responsible use of AI in cooperation with clients. The consultancy also set up an AI business task force early in 2023 and developed over 250 use cases last year. BearingPoint is delivering innovative solutions for its clients, including implementing a global GenAI vision for a top retail chain, creating an AI banking avatar for a large international bank, simplifying daily police work with an AI for a police department, and automating the creation of annual reports for an NGO.

BearingPoint has also supported many clients on their sustainability and decarbonization journeys, through integrated sustainability advisory and products as well as launching innovative new services including the BearingPoint Sustainability Maturity Assessment, the ESG Data Hub and the I Care Academy. BearingPoint has provided clients with streamlined ESG reporting support and enhanced sustainability transformation programs. Moreover, the firm invested more than 1,000 consulting days in CSR activities and ran numerous Climate Fresk workshops throughout the year.

People development is a top priority

In 2023, BearingPoint appointed 27 new Partners to the firm and promoted 1,398 people, the largest-ever cohort, reflecting the strength of the organization and its confidence in the future. BearingPoint made record investments in learning and people development and delivered an all-time-high of 260,000 training hours. BearingPoint provides a range of programs, such as Be.Oxford Academy, Be.School, Female Leadership, and the Yale Leadership Program. Over 2,200 people participated in these programs in 2023, a year which saw BearingPoint also open its Be.Campus in Brussels, where the firm will deliver even more trainings in 2024.

2024 – Strategy acceleration continues

In 2024, BearingPoint wants to outperform the market again and accelerate its strategy execution further, planing a double-digit organic revenue growth. In addition, the consultancy sees more strategic M&A activities and investments in developing its consulting and products portfolio in 2024, especially in focus areas such as sustainability and in key geographies such as the US. BearingPoint also said its joint venture Arcwide will continue to expand to become the IFS delivery partner of choice for enterprise organizations worldwide.

“As we look towards the future, BearingPoint is in an excellent position to grow and expand further. We are faithful to our values, empower people to succeed, and create lasting outcomes for our clients, society, and the planet,” said Kiumars Hamidian.

About BearingPoint

BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.

BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.

For more information, please visit:

Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
X: @BearingPoint

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240205345183/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye